Neoadjuvant nivolumab plus ipilimumab in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors: ECOG-ACRIN EA2201

被引：0

作者：

Ciombor, K. K. ^{[1
]}

Hong, S. ^{[2
]}

Eng, C. ^{[3
]}

Yao, X. ^{[4
]}

You, N. ^{[5
]}

Das, P. ^{[6
]}

Chakravarthy, A. ^{[7
]}

O'Dwyer, P. J. ^{[8
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Internal Med Hematol Oncol Dept, Preston Canc Res Bldg, Nashville, TN USA

[2] Dana Farber Canc Inst, Data Sci, Boston, MA USA

[3] Vanderbilt Ingram Canc Ctr, Hematol Oncol Dept, Nashville, TN USA

[4] Cleveland Clin Florida, Oncol, Weston, FL USA

[5] Univ Texas MD Anderson Canc Ctr, Colorectal Surg, Houston, TX USA

[6] Univ Texas MD Anderson Canc Ctr, Radiol Oncol, Houston, TX USA

[7] Vanderbilt Univ, Med Ctr, Radiat Oncol, Nashville, TN USA

[8] ECOG ACRIN Canc Res Grp, Med Oncol Dept, Philadelphia, PA USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.249

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

242MO

引用

页码：S104 / S104

页数：1

共 50 条

[41] Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer
Morse, Michael A.
Overman, Michael J.
Hartman, Leighanne
Khoukaz, Taline
Brutcher, Edith
Lenz, Heinz-Josef
Atasoy, Ajlan
Shangguan, Tong
Zhao, Huanyu
El-Rayes, Bassel
ONCOLOGIST, 2019, 24 (11): : 1453 - 1461
[42] RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II study
Cohen, Romain
Bennouna, Jaafar
Henriques, Julie
Tournigand, Christophe
De La Fouchardiere, Christelle
Tougeron, David
Borg, Christophe
Mazard, Thibault
Chibaudel, Benoist
Garcia-Larnicol, Marie-Line
Svrcek, Magali
Vernerey, Dewi
Menu, Yves
Andre, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[43] Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial
Bi, Feng
Dong, Jian
Jin, Chuan
Niu, Zuoxing
Yang, Wenhui
He, Yifu
Yu, Dajun
Sun, Meili
Wang, Teng
Yin, Xianli
Zhang, Ruixing
Chen, Kehe
Wang, Keming
Wang, Zhiwu
Li, Wei
Zhang, Zhongtao
Zhang, Hangyu
Guo, Qunyi
Wang, Xin
Han, Lei
Zhang, Xizhi
Shen, Wei
Zhang, Liangming
Ying, Jieer
Wu, Miao
Hu, Weiguo
Li, Zeng
Li, Xiaofen
Feng, Wenlei
Zhang, Baihui
Li, Lingyan
Kang, Xiaoyan
Guo, Weijian
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
[44] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142
Lenz, Heinz-Josef
Overman, Michael J.
Van Cutsem, Eric
Limon, Maria Luisa
Wong, Ka Yeung Mark
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Gelsomino, Fabio
Cardin, Dana Backlund
Dragovich, Tomislav
Shah, Usman
McCraith, Stephen
Wang, Rui
Lei, Ming
Yao, Jin
Jin, Lixian
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 97 - 97
[45] Initial findings from the DREAM-GI national database: Assessing the efficacy and safety of neoadjuvant immunotherapy (NIT) in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastrointestinal (GI) cancer.
Chakrabarti, Sakti
Selfridge, J. Eva
Parish, Marie
Bajor, David L.
Ruggeri, Antony
Tolay, Sameer
Conces, Madison
Lumish, Melissa Amy
Mohamed, Amr
Mahipal, Amit
Shreenivas, Aditya V.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 736 - 736
[46] Genomic landscapes to characterize mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers stratified by tumor mutation burden (TMB)
Wang, Jingyuan
Xiu, Joanne
Farrell, Alex Patrick
Battaglin, Francesca
Arai, Hiroyuki
Millstein, Joshua
Soni, Shivani
Zhang, Wu
Shields, Anthony F.
Grothey, Axel
Weinberg, Benjamin Adam
Marshall, John
Lou, Emil
Khushman, Moh'd M.
Sohal, Davendra
Hall, Michael J.
Oberley, Matthew James
Spetzler, David
Lenz, Heinz-Josef
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab plus ipilimumab in CheckMate-142
Kopetz, Scott
Andre, Theirry
Overman, Michael J.
Zagonel, Vittorina
Lonardi, Sara
Aglietta, Massimo
Gelsomino, Fabio
McDermott, Ray
Wong, Ka Yeung Mark
Hendlisz, Alain
Garcia Alfonso, Pilar
Lenz, Heinz-Josef
Walsh, Alice
Moss, Rebecca A.
Greenawalt, Danielle
Cao, Z. Alexander
CANCER RESEARCH, 2018, 78 (13)
[48] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study
Andre, Thierry
Elez, Elena
Van Cutsem, Eric
Jensen, Lars Henrik
Bennouna, Jaafar
Mendez, Guillermo
Schenker, Michael
De La Fouchardiere, Christelle
Limon, Maria Luisa
Yoshino, Takayuki
Li, Jin
Lenz, Heinz-Josef
Manzano Mozo, Jose Luis
Tortora, Giampaolo
Garcia-Carbonero, Rocio
Cela, Elvis
Yang, Yingsi
Lei, Ming
Jin, Lixian
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : LBA768 - LBA768
[49] Exploratory Analysis of Janus Kinase 1 (JAK1) Loss-of-Function (LoF) Mutations in Patients with DNA Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Metastatic Colorectal Cancer (mCRC) Treated with Nivolumab plus Ipilimumab in CheckMate-142
Kopetz, S.
Andre, T.
Overman, M. J.
Zagonel, V.
Lonardi, S.
Aglietta, M.
Gelsomino, F.
McDermott, R.
Wong, K. Y. M.
Hendlisz, A.
Alfonso, P. G.
Lenz, H. J.
Walsh, A.
Moss, R. A.
Greenawalt, D.
Cao, Z. A.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2018, 20 (03): : S3 - S3
[50] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142
Lenz, Heinz-Josef
Overman, Michael J.
Van Cutsem, Eric
Limon, M. Luisa
Wong, Mark Ka
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Gelsomino, Fabio
Cardin, Dana Backlund
Dragovich, Tomislav
Shah, Usman
McCraith, Stephen M.
Wang, Abigail
Lei, Ming
Yao, Jin
Jin, Lixian
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →